Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 5/20 | 0.58 |
| ▸ | EGFR | P00533 | 5/20 | 0.41 |
| ▸ | HCAR1 | Q9BXC0 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4565717 | 0.84 | TERT (0.56) | TERTPDE5AHDAC1HDAC2HDAC6 | |
| SCHEMBL7960724 | 0.82 | TERT (0.65) | TERTALDH1A1MAPTSMN1; SMN2PDE5A | |
| SCHEMBL30357138 | 0.80 | TERT (0.65) | TERTALDH1A1MAPT | |
| SCHEMBL1792 | 0.80 | TERT (0.65) | TERTALDH1A1MAPT | |
| SCHEMBL8125815 | 0.79 | TERT (0.62) | TERTALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL12380564 | 0.78 | KDM4E (0.52) | EGFRALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL7006683 | 0.77 | TERT (0.58) | TERTKDM4EPDE5AHDAC1HDAC2 | |
| SCHEMBL7253729 | 0.77 | TERT (0.58) | TERTKDM4EPDE5AHDAC1HDAC2 | |
| SCHEMBL6207835 | 0.76 | TERT (0.65) | TERTMAPTPDE5A | |
| SCHEMBL6332500 | 0.76 | KMT2A (0.52) | TERTPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221825-B2 | Pyrazolopyrimidinone compound and imidazo triazone compound for treating erectile dysfunction | ZHEJIANG DADE PHARMACEUTICAL GROUP CO., LTD. (CN) | 2015-12-29 | — | — | US | disclosed |
| US-20140018351-A1 | Pyrazolopyrimidinone Compound and Imidazo Triazone Compound for Treating Erectile Dysfunction | Zhejiang Date Pharmaceutical Group Co. Ltd (CN) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018351-A1 | Pyrazolopyrimidinone Compound and Imidazo Triazone Compound for Treating Erectile Dysfunction | PDE3A, PDE3B, PDE5A | TERT 1504/4885EGFR 4827/4885HCAR1 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.